Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models.
DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years ...
Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management ...
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how automation cuts human touches, enforces quarantine and ...
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern ...
EVERSANA is folding Estima Scientific's AI-powered HEOR tools into its market access offerings as its CEO says evidence ...
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a ...
BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase ...
Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical ...
Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results